ATE242635T1 - Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren - Google Patents

Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren

Info

Publication number
ATE242635T1
ATE242635T1 AT97921396T AT97921396T ATE242635T1 AT E242635 T1 ATE242635 T1 AT E242635T1 AT 97921396 T AT97921396 T AT 97921396T AT 97921396 T AT97921396 T AT 97921396T AT E242635 T1 ATE242635 T1 AT E242635T1
Authority
AT
Austria
Prior art keywords
treatment
treatment procedure
squalamine
procedure
cytotoxic chemical
Prior art date
Application number
AT97921396T
Other languages
English (en)
Inventor
Michael Zasloff
Jon Williams
Original Assignee
Magainin Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Pharma filed Critical Magainin Pharma
Application granted granted Critical
Publication of ATE242635T1 publication Critical patent/ATE242635T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97921396T 1996-04-26 1997-04-25 Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren ATE242635T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1638796P 1996-04-26 1996-04-26
PCT/US1997/007011 WO1997040835A1 (en) 1996-04-26 1997-04-25 Treatment of carcinomas using squalamine in combination with other anti-cancer agents

Publications (1)

Publication Number Publication Date
ATE242635T1 true ATE242635T1 (de) 2003-06-15

Family

ID=21776862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921396T ATE242635T1 (de) 1996-04-26 1997-04-25 Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren

Country Status (11)

Country Link
US (1) US6147060A (de)
EP (1) EP0910382B1 (de)
JP (1) JP2000510460A (de)
AT (1) ATE242635T1 (de)
AU (1) AU735884B2 (de)
CA (1) CA2252584C (de)
DE (1) DE69722793T2 (de)
DK (1) DK0910382T3 (de)
ES (1) ES2201296T3 (de)
PT (1) PT910382E (de)
WO (1) WO1997040835A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
EP1105407B1 (de) * 1998-08-12 2007-10-10 Genaera Corporation Aminosterolderivate und ihre verwendungen
EP1119361A4 (de) * 1998-09-10 2006-10-04 Magainin Pharma Behandlung von karzinomen mit squalamin in kombination mit anderen anti-tumor-agenzien
DK1156823T3 (da) * 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
ES2344831T3 (es) 2000-06-23 2010-09-08 Mitsubishi Tanabe Pharma Corporation Potenciadores de un efecto antitumoral.
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
EP1424889A4 (de) * 2001-08-20 2008-04-02 Transave Inc Verfahren zur behandlung von lungenkarzinomen
CA2457148A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
MXPA05004580A (es) * 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US20080194019A1 (en) * 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
CN101031287A (zh) * 2004-03-02 2007-09-05 麻省理工学院 纳米细胞药物递送系统
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
JP2008500397A (ja) * 2004-05-21 2008-01-10 トランセイブ， インク． 肺疾患及び前肺疾患状態の治療
JP2008514726A (ja) * 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
JP5735724B2 (ja) * 2004-11-08 2015-06-17 インスメッド， インコーポレイテッド 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
CA2606077C (en) 2005-04-25 2013-07-09 Genaera Corporation Polymorphic and amorphous salt forms of squalamine dilactate
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
PL1962805T3 (pl) 2005-12-08 2017-01-31 Insmed Incorporated Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych
AU2008224929A1 (en) * 2007-03-14 2008-09-18 Mayo Foundation For Medical Education And Research Treating skin cancer
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9611313B2 (en) * 2007-06-26 2017-04-04 University Of Miami Antibody-endostatin fusion protein and its variants
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
US8729058B2 (en) * 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
US8623416B2 (en) * 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
PL2831110T3 (pl) * 2012-03-30 2018-11-30 The Regents Of The University Of California Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
KR102277921B1 (ko) 2012-05-21 2021-07-14 인스메드 인코포레이티드 폐 감염을 치료하기 위한 시스템
WO2014039533A2 (en) 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
CA2917407C (en) 2012-10-01 2023-03-14 Mayo Foundation For Medical Education And Research Complexes containing albumin-containing nanoparticles and antibodies to treat cancer
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
MX2016016617A (es) 2014-06-16 2017-03-23 Mayo Foundation Tratamiento de mielomas.
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (de) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research Verfahren zur behandlung von krebs mit interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
ES2937291T3 (es) 2016-09-01 2023-03-27 Mayo Found Medical Education & Res Composiciones de agentes que se unen al transportador PD-L1 y métodos de uso de las mismas para tratar cánceres
KR20190053203A (ko) 2016-09-01 2019-05-17 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｔ－세포 암을 표적화하는 방법 및 조성물
MX2019002564A (es) 2016-09-06 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
AU2017324335A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Methods of treating PD-L1 expressing cancer
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2019050903A1 (en) 2017-09-08 2019-03-14 Enterin Laboratories, Inc. METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
WO2019089603A1 (en) * 2017-10-31 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods for determining and treating cellular resistance to adp-ribosylating toxin
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016390A (en) * 1960-06-30 1962-01-09 Searle & Co N-(substituted alkyl) amino-5alpha-androstan-17beta-ols
US3370070A (en) * 1965-06-16 1968-02-20 Searle & Co [n-alkyl-17-(dialkylaminoalkyl)amino] androst-4-en-3-ones
GB1565351A (en) * 1975-06-02 1980-04-16 Theramex Steroid aminoethers
US4220598A (en) * 1977-11-14 1980-09-02 Abbott Laboratories Method and reagents for measuring the level of conjugated bile acids
US4550163A (en) * 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US4372888A (en) * 1980-08-26 1983-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Nondenaturing zwitterionic detergents
JPS5842878B2 (ja) * 1981-12-02 1983-09-22 名糖産業株式会社 １２−オキソコラン酸トシルヒドラゾン化合物、その製法ならびに利用
DE3366932D1 (en) * 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US4545938A (en) * 1983-11-02 1985-10-08 Beth Israel Medical Center Chemical synthesis
JPS6133121A (ja) * 1984-07-25 1986-02-17 Nissei Marine Kogyo Kk 制癌剤
US4917826A (en) * 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
JPS62175497A (ja) * 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
US5075464A (en) * 1987-04-22 1991-12-24 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropylamino)androstene derivatives
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
IT1229569B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US4966897A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
JPH05507912A (ja) * 1990-06-11 1993-11-11 アルコン・ラボラトリーズ，インコーポレイテッド 血管形成を阻害するステロイド
ES2096614T3 (es) * 1990-12-06 1997-03-16 Hoechst Ag Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de este compuesto como medicamento.
US5192756A (en) * 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
AU4534593A (en) * 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU6392894A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
ATE169930T1 (de) * 1993-03-10 1998-09-15 Magainin Pharma Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
PT749437E (pt) * 1994-03-10 2002-03-28 Magainin Pharma Utilizacoes farmaceuticas de derivados de esteroides
CA2223910C (en) * 1995-06-07 2008-09-16 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine

Also Published As

Publication number Publication date
JP2000510460A (ja) 2000-08-15
EP0910382B1 (de) 2003-06-11
DK0910382T3 (da) 2003-10-06
CA2252584A1 (en) 1997-11-06
WO1997040835A1 (en) 1997-11-06
US6147060A (en) 2000-11-14
DE69722793T2 (de) 2004-05-19
AU2744197A (en) 1997-11-19
DE69722793D1 (de) 2003-07-17
PT910382E (pt) 2003-10-31
AU735884B2 (en) 2001-07-19
ES2201296T3 (es) 2004-03-16
EP0910382A1 (de) 1999-04-28
CA2252584C (en) 2008-06-10

Similar Documents

Publication Publication Date Title
ATE242635T1 (de) Squalamin in kombination mit anderen antikrebs- mittelen zur behandlung von tumoren
RU2430739C2 (ru) Способ лечения рака у человека (варианты), применяемая в способе форма (варианты) и применение антитела (варианты)
D'Angio et al. Potentiation of x-ray effects by actinomycin D
US4971991A (en) Physiological function enhancing agents activated by ultrasonic waves for the treatment of tumors
Ingrand Characteristics of radio-isotopes for intra-articular therapy.
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
BR0109517A (pt) métodos e composições sinérgicas para tratar o cáncer
Dombernowsky et al. Combination chemotherapy with 4′ Demethylepipodophyllotoxin 9-(4, 6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 Leukemia
RU2007134571A (ru) Комбинация и способы введения терапевтических средств и комбинированной терапии
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
RU2007101378A (ru) Терапия злокачественной опухоли, резистентной к препаратам на основе платины
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
DE69320646D1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
BR8905657A (pt) Processo para preparar um quelante bifuncional,processo para preparar um complexo de um composto,processo para preparar um conjugado e processo para preparar uma formulacao farmaceutica
SE8602743D0 (sv) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
ATE485818T1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
EP0281070A3 (de) Pharmazeutische Zusammensetzung für die Krebsbehandlung
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
Harstrick et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer
HUT68876A (en) Pharmaceutical composition for treating tumours, containing creatine phosphate or phospho-enol-pyruvic acid
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
ES465180A1 (es) Procedimiento para la preparacion de preparados de inmuno- globulinas
Canellos Lymphoma: present and future challenges

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0910382

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee